NCT06237192View on ClinicalTrials.gov

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2027

Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions
DRUG

blinatumomab for B-ALL, venetoclax for T-ALL

MRD-associated based therapy for Ph-negative acute lymphoblastic leukemia

Trial Locations (1)

Unknown

RECRUITING

Olga Aleshina, Moscow

All Listed Sponsors
lead

National Research Center for Hematology, Russia

NETWORK